Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Apr;69(2):142–149. doi: 10.1016/j.curtheres.2008.04.007

Effects of clozapine administration on body weight, glucose tolerance, blood glucose concentrations, plasma lipids, and insulin in male C57BL/6 mice: A parallel controlled study

Hai-Yan Yuan 1, Hai-Xia Liang 1, Guang-Rong Liang 2, Gui-Xiang Zhang 3, Huan-De Li 1,a
PMCID: PMC3969929  PMID: 24692793

Abstract

Background: Clozapine has been associated with metabolic adverse events (AEs) (eg, elevated body weight, blood glucose concentrations, cholesterol, triglycerides [TG]), all of which have deleterious effects on health and medication compliance. However, little focus has been directed toward finding a suitable experimental model to study the metabolic AEs associated with clozapine.

Objective: The aim of this study was to assess the effects of clozapine administration for 28 days on body weight, glucose tolerance, blood glucose concentrations, plasma lipids, and insulin in C57BL/6 mice.

Methods: C57BL/6 mice were grouped and treated with clozapine 2 or 10 mg/kg or vehicle intraperitoneally QD for 28 days. Body weight was assessed on days 0 (baseline), 7, 14, 21, and 28, and glucose tolerance, blood glucose concentrations, insulin (calculated by insulin resistance index [IRI]), and plasma lipids (including total cholesterol, TG, high-density lipoprotein cholesterol [HDL-C], and low-density lipoprotein cholesterol) were assessed on day 29.

Results: Sixty 10-week-old, male C57BL/6 mice were included in the study and were divided into 3 groups (20 mice per group). The body weight significantly decreased in the clozapine 10-mg-treated group on days 14, 21, and 28 compared with the vehicle group (mean [SD] body weight: 21.61 [1.05] vs 22.79 [1.11], 22.53 [1.05] vs 24.17 [1.24], and 22.21 [1.07] vs 24.99 [1.39] g, respectively; all, P < 0.05). In the clozapine 10-mg/kg group, blood glucose concentrations significantly increased 0, 30, 60, and 120 minutes after glucose administration compared with the vehicle group (mean [SD]: 6.67 [1.25], 25.34 [5.85], 12.68 [3.39], and 7.52 [1.45] mmol/L, respectively, vs 4.61 [0.78], 21.54 [6.55], 11.46 [3.46], and 6.55 [1.42] mmol/L, respectively; all P < 0.05). The clozapine 10-mg/kg group also had significant increases in plasma insulin concentrations compared with the vehicle group (12.70 [5.27] vs 7.62 [4.54] μIU/mL; P < 0.05) and IRI (3.01 [1.26] vs 1.51 [0.96]; P < 0.05). Plasma HDL-C concentration also significantly decreased in the clozapine 10-mg/kg group compared with the vehicle group (1.23 [0.25] vs 1.47 [0.16]; P < 0.05).

Conclusion: Clozapine 10 mg/kg was associated with significant decreases in body weight and significant increases in fasting blood glucose and glucose tolerance in these male C57BL/6 mice.

Key words: clozapine, body weight, blood glucose, insulin resistance, plasma lipid, mice

Full Text

The Full Text of this article is available as a PDF (819.9 KB).

References

  • 1.Kane JM. Br J Psychiatry Suppl. 1992. Clinical efficacy of clozapine in treatment-refractory schizophrenia: An overview. pp. 41–45. [PubMed] [Google Scholar]
  • 2.Henderson DC. Clozapine: Diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry. 2001;62:39–44. [PubMed] [Google Scholar]
  • 3.Henderson DC, Cagliero E, Copeland PM. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: A frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62:19–28. doi: 10.1001/archpsyc.62.1.19. [DOI] [PubMed] [Google Scholar]
  • 4.Henderson DC, Cagliero E, Gray C. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000;157:975–981. doi: 10.1176/appi.ajp.157.6.975. [DOI] [PubMed] [Google Scholar]
  • 5.Dwyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav. 2003;75:255–260. doi: 10.1016/s0091-3057(03)00079-0. [DOI] [PubMed] [Google Scholar]
  • 6.Cheng CY, Hong CJ, Tsai SJ. Effects of subchronic clozapine administration on serum glucose, cholesterol and triglyceride levels, and body weight in male BALB/c mice. Life Sci. 2005;76:2269–2273. doi: 10.1016/j.lfs.2004.12.004. [DOI] [PubMed] [Google Scholar]
  • 7.Arulmozhi DK, Dwyer DS, Bodhankar SL. Antipsychotic induced metabolic abnormalities: An interaction study with various PPAR modulators in mice. Life Sci. 2006;79:1865–1872. doi: 10.1016/j.lfs.2006.06.016. [DOI] [PubMed] [Google Scholar]
  • 8.Tulipano G, Rizzetti C, Bianchi I. Clozapine-induced alteration of glucose homeostasis in the rat: The contribution of hypothalamic-pituitary-adrenal axis activation. Neuroendocrinology. 2007;85:61–70. doi: 10.1159/000100981. [DOI] [PubMed] [Google Scholar]
  • 9.Norman D, Hiestand WA. Glycemic effects of chlorpromazine in the mouse, hamster and rat. Proc Soc Exp Biol Med. 1955;90:89–91. doi: 10.3181/00379727-90-21947. [DOI] [PubMed] [Google Scholar]
  • 10.Zielasek J, Kolb H. Ganglioside therapy of type I diabetes: enhancement of hyperglycemia in the low dose streptozotocin model. Life Sci. 1992;51:49–52. doi: 10.1016/0024-3205(92)90217-d. [DOI] [PubMed] [Google Scholar]
  • 11.Tomie Furuya D, Binsack R, Onishi ME. Low ethanol consumption induces enhancement of insulin sensitivity in liver of normal rats. Life Sci. 2005;77:1813–1824. doi: 10.1016/j.lfs.2004.12.046. [DOI] [PubMed] [Google Scholar]
  • 12.Rolsten C, Claghorn J, Samorajski T. Long-term treatment with clozapine on aging mice. Life Sci. 1979;25:865–872. doi: 10.1016/0024-3205(79)90544-7. [DOI] [PubMed] [Google Scholar]
  • 13.Baptista T, Mata A, Teneud L. Effects of long-term administration of clozapine on body weight and food intake in rats. Pharmacol Biochem Behav. 1993;45:51–54. doi: 10.1016/0091-3057(93)90084-7. [DOI] [PubMed] [Google Scholar]
  • 14.Cooper GD, Pickavance LC, Wilding JP. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 2005;181:80–89. doi: 10.1007/s00213-005-2224-4. [DOI] [PubMed] [Google Scholar]
  • 15.Patil BM, Kulkarni NM, Unger BS. Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain. Eur J Pharmacol. 2006;551:112–115. doi: 10.1016/j.ejphar.2006.09.009. [DOI] [PubMed] [Google Scholar]
  • 16.Ardizzone TD, Bradley RJ, Freeman AM, III, Dwyer DS. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res. 2001;923:82–90. doi: 10.1016/s0006-8993(01)03026-8. [DOI] [PubMed] [Google Scholar]
  • 17.Wirshing DA, Boyd JA, Meng LR. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63:856–865. doi: 10.4088/jcp.v63n1002. [DOI] [PubMed] [Google Scholar]
  • 18.Lindenmayer JP, Czobor P, Volavka J. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160:290–296. doi: 10.1176/appi.ajp.160.2.290. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES